Diabetes Research and Clinical Practice
Volume 65, Issue 2 , Pages 125-133 , August 2004

Cardiovascular risk factors in patients with type 2 diabetes: Do we follow the guidelines?

  • Francisco Javier del Cañizo-Gómez

      Affiliations

    • Endocrinology Unit, Hospital Virgen de la Torre, Puerto Lumbreras 5, 28031 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Present address: Travesı́a Mare Nostrum 23, 28220 Majadahonda, Madrid, Spain. Tel.: +34-1-6386540; fax: +34-1-6386540.
    • ,
  • Marı́a Natividad Moreira-Andrés

      Affiliations

    • Department of Endocrinology, Hospital Universitario 12 de Octubre, Carretera de Andalucı́a Km. 5.400, 28041 Madrid, Spain

,Revised 22 October 2003 ,Accepted 9 December 2003.

References 

  1. The Framingham Heart Study, a general cardiovascular risk profile, Am. J. Cardiol. 38 (1976) 46–51.
  2. Fuller JH, Shipley MJ, Rose G, Jarrett RJ, Keen H. Mortality from coronary heart disease and stroke in relation to degree of glicaemia: the Whitehall Study. Br. Med. J. 1983;287:867–870
  3. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am. J. Epidemiol. 2002;156:714–719
  4. Stern MP. Glycemia and cardiovascular risk. Diabetes Care. 1997;20:1501–1502
  5. Diabetes Drafting Group, Prevalence of small vessel and large vessel disease in diabetic patients from 14 centres, The World Health Organization Multinational Study of Vascular Disease in Diabetics, Diabetologia 28 (Suppl. 1) (1985) 615–640.
  6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 1998;339:229–234
  7. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross-sectional and cohort studies. Br. Med. J. 2002;324:939–942
  8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;348:383–393
  9. UK Prospective Diabetes Study (UKPDS), Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38), Br. Med. J. 317 (1998) 703–713.
  10. Ashwell M, Chinn S, Stalley S, Garrow JS. Female fat distribution—a simple classification based on two circumference measurements. Int. J. Obes. 1982;6:143–152
  11. American Diabetes Association, Standards of medical care for patients with diabetes mellitus, Diabetes Care 26 (Suppl. 1) (2003) S33–S50.
  12. WHO, Programme of Nutrition, Family and Reproductive Health Obesity, Preventing and managing the global epidemic, Report of WHO consultation on obesity, Geneva WHO, 1998.
  13. George PB, Tobin KJ, Corpus RA, Devlin WH, O’Neill WW. Treatment of cardiac risk factors in diabetic patients: how well do we follow the Guidelines?. Am. Heart J. 2001;142:857–863
  14. Spijkerman AM, Dekker JM, Nijpels G, et al.  Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur. J. Clin. Invest. 2002;32:924–930
  15. Jovanovic L. Rationale for prevention and treatment of postprandial glucose-mediated toxicity. Endocrinologist. 1999;9:87–92
  16. Avignon A, Radauceanu A, Monnier L. Non-fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care. 1997;20:1822–1826
  17. Shaw JE, Hodge AM, Courten M, Chitson P, Zimmet PZ. Isolated post-challenge hyperglycaemic confirmed as a risk factor for mortality. Diabetologia. 1999;42:1050–1054
  18. Pyörälä K, Pedersen TL, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study. Diabetes Care. 1997;20:614–620
  19. Rubins HB, Robins SJ, Collins D, et al.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 1999;341:410–418
  20. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 patients people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–2016
  21. Gotto AM, Phil D. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am. Heart J. 2002;144:S33–S42
  22. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434–444
  23. UK Prospective Diabetes Study (UKPDS) Group, Efficacy of atenolol and captopril in reducing the risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 39), Br. Med. J. 317 (1998) 713–720.
  24. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitors treatment: HOPE and MICRO-HOPE. Diab. Metab. Res. 2002;18:S82–S85
  25. Lewis EJ, Hunsicker LG, Clarke WR, et al.  Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001;345:851–860
  26. Molarius A, Seidell JC. Selection of anthropometric indicators for classification of abdominal fatness—a critical review. Int. J. Obes. Relat. Metab. Disord. 1998;22:719–727
  27. Pouliot MC, Desprès JP, Lemieux S, et al.  Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am. J. Cardiol. 1994;73:460–468
  28. Wilson PW, D’Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk: the Framingham Experience. Arch. Intern. Med. 2002;162:1867–1872
  29. Wilson PW, Kannel WB. Obesity, diabetes and risk of cardiovascular disease in the elderly. Am. J. Geriatr. Cardiol. 2002;11:119–123
  30. Brochu M, Starling RD, Tchernoff A, Matthews DE, Garcı́a-Rubı́ E, Poehlman ET. Visceral adipose tissue is an independent correlate of glucose disposal in older obese postmenopausal women. J. Clin. Endocrinol. Metab. 2000;85:2378–2384
  31. Al-Delaimy WK, Manson JE, Solomon CG, et al.  Smoking and risk of coronary heart disease among women with type 2 diabetes mellitus. Arch. Intern. Med. 2002;162:273–279
  32. Jonas M, Reicher-Reiss H, Boyko V, et al.  Usefulness of beta-blocker therapy in patients with non-insulin dependent diabetes mellitus and coronary artery disease. Am. J. Cardiol. 1996;77:1273–1277
  33. Groop L, Totterman KJ, Harnok GA. Influence of beta-blocking drugs on glucose metabolism in patients with non-insulin dependent diabetes mellitus. Acta Med. Scand. 1982;211:7–12
  34. Antiplatelet Trialists’ Collaboration, Secondary prevention of vascular disease by prolonged antiplatelet treatment, Br. Med. J. (Clin. Res. Ed.) 296 (1988) 320–331.
  35. American Diabetes Association, Aspirin therapy in diabetes, Diabetes Care 26 (Suppl. 1) (2003) S87–S88.

PII: S0168-8227(03)00333-4

doi: 10.1016/j.diabres.2003.12.002

Diabetes Research and Clinical Practice
Volume 65, Issue 2 , Pages 125-133 , August 2004

Article Tools

* Image Usage & Resolution